The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Improving access to information on new treatments: A key to shared treatment decision-making
Rachel Saks
September 3, 2024
Know AML conducted a poll among patients with acute myeloid leukemia (AML), as well as their families and caregivers, which highlighted concerns regarding the availability of information on current treatment options. Know AML was pleased to speak with Rachel Saks, Senior Director of Education and Programs at Cancer Support Community and Know AML ambassador. We asked, What can we do to make information on newer treatments more readily available, and why is this information important to inform shared treatment decision-making?
Rachel explains that shared decision-making is a process where patients and healthcare providers work together to choose a care plan that reflects the patient's goals and treatment preferences. Hence, access to up-to-date treatment information is crucial, and can be achieved through collaboration among healthcare professionals, advocacy groups, community members, and patients. Additionally, patients and caregivers should actively engage with organizations to support education, resource development, and policy initiatives.
